[Changes of lymphocyte subpopulation in advanced renal cell carcinoma patients with marked response to alpha-interferon therapy].
At present, no sufficient therapy for advanced renal cell carcinoma is available. Interferon (IFN) therapy has been used to treat renal cell carcinoma, but the efficacy of it is low, with response rate being only about 20%. We experienced two patients with advanced renal cell carcinoma had marked response to IFN-alpha therapy in proximity effect. Using monoclonal anti-bodies of each subset of lymphocytes, the peripheral blood lymphocytes (PBL) in these patients were evaluated by two color flow-cytometry. And these results and clinical course were assessed. The lymphocyte subpopulation that change of clinical course is been similar to in these patients were Tc (CD11b-CD8+), TSI (leu8+ CD4+), ATS/C (CD8+ HLA-DR+) and ATH/SI (CD4+ HLA-DR+). And the pretherapeutic immunological status of these patients was characterized by significantly increased CD4+/CD8+ and TH/TS ratio. In conclusion, the clinical response of advanced renal cell carcinoma to IFN therapy might be found if CD4+/CD8+ and TH/TS ratio are increased at pretherapeutic immunological status. In addition, assessment of TSI, TC, ATH/SI, and ATS/C, as immune parameters for monitoring the actual immune status of patient is found to be necessary part of immunotherapy.
Kobayashi
Y
Y
Department of Urology, Jichi Medical School.
Yuzawa
M
M
Sugaya
Y
Y
Kikuchi
T
T
Morita
T
T
Tokue
A
A
D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000628:therapy; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000276:immunology* / Q000628:therapy; D008297:Male; D016176:T-Lymphocyte Subsets
D016898:Interferon-alpha